Johnson & Johnson (JNJ) 103.10 $JNJ
Final Glance: Medical Devices companies
AP - Fri Aug 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Fri Aug 22, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:55PM CDT
Bristol-Myers (BMY) and partner Pfizer (PFE) announced that the FDA has cleared Eliquis for an additional indication.
Eli Lilly Uncovers Positive Data from Ixekizumab Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:45PM CDT
Eli Lilly and Company (LLY) announced encouraging results from three studies under theUNCOVER program on ixekizumab.
Omnicom Offers Steady Profit Growth, Rising Dividend
at Investor's Business Daily - Fri Aug 22, 4:25PM CDT
Omnicom Group (OMC), the biggest U.S. advertising company, is seeing profits improve as the global economy continues to grow. The New York City-based firm has reported two straight quarters of accelerating profit increases, to 10% in the latest...
Johnson & Johnson vs. Abbott Laboratories in the Battle for Emerging Market Turf
at The Street - Fri Aug 22, 3:55PM CDT
Emerging market pharmaceutical sales are exploding. Find out if Abbott Laboratories or Johnson & Johnson is best positioned to take advantage of the booming emerging market pharmaceutical market.
3 Reasons Bristol-Myers Squibb's Stock Could Rise
George Budwell, The Motley Fool - Motley Fool - Fri Aug 22, 3:47PM CDT
The patent cliff has forced most Big Pharmas to make major transformations in their businesses over the past few years. Bristol-Myers Squibb in particular has been ravaged by the loss of patent protection for blood thinner Plavix and a host of...
Midday Glance: Pharmaceuticals companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Johnson & Johnson (JNJ) Approaches New Downside Target of $102.89
Comtex SmarTrend(R) - Fri Aug 22, 10:24AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bearishly opened below the pivot of $103.98 today and have reached the first support level of $103.54. Should the shares continue to fall, the support pivots of $102.89 and $101.80 will be of interest.
Intel, Home Depot, Microsoft Lead DJIA During Earnings Season
at The Street - Fri Aug 22, 8:00AM CDT
On Thursday, Home Depot became the last Dow component to report quarterly results. Here's how the 30 stocks in the DJIA fared during earnings season.
Illumina lines up key partners
at Investor's Business Daily - Thu Aug 21, 5:41PM CDT
DNA sequencing gear maker Illumina (ILMN) struck strategic partnerships with several big drugmakers to develop a universal sequencing-based oncology test system for cancer diagnosis. Its initial partners for the project include AstraZeneca (AZN),...
Apple Stock Held By Institutional Investors Rises
at Investor's Business Daily - Thu Aug 21, 4:02PM CDT
Ownership of Apple (AAPL) stock by institutional investment firms edged up 1.3% in the second quarter from Q1, as confidence in the company's performance rose. The increase follows a 4.3% decline in Q1 from Q4, reports FactSet Research. Though the Q2...
Dow Component Johnson & Johnson (JNJ) To Go Ex-dividend Tomorrow
at The Street - Thu Aug 21, 10:00AM CDT
Friday, August 22, 2014 is the ex-dividend date for Dow component (NYSE:JNJ).
Must-See Charts: Still Time to Buy These 5 Stocks
at The Street - Thu Aug 21, 9:09AM CDT
Here's how to trade some of the biggest stocks on Wall Street.
Dow Today: Johnson & Johnson (JNJ) Leads The Day Higher, Boeing (BA) Lags
at The Street - Thu Aug 21, 9:00AM CDT
The Dow component leading the way higher looks to be Johnson & Johnson (NYSE:JNJ), which is sporting a 67-cent gain (+0.7%) bringing the stock to $103.88. Holding back the Dow today is Boeing (NYSE:BA), which is lagging the broader Dow index with a...
The Zacks Analyst Blog Highlights: Johnson & Johnson, Tekmira Pharmaceuticals, GileadSciences, Allergan and Supernus Pharmaceuticals
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Johnson & Johnson (NYSE:JNJ-Free Report), Tekmira Pharmaceuticals Corp (Nasdaq:TKMR-Free Report), Gilead Sciences Inc. (Nasdaq:GILD-Free Report), Allergan Inc. (NYSE:AGN-Free Report) and Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN-Free Report).
ViaCyte, Inc. Announces Signing of Rights Agreement with Janssen Research & Development LLC.
PR Newswire - Thu Aug 21, 8:00AM CDT
ViaCyte, Inc., a privately held regenerative medicine company announced today that it has entered into a Rights Agreement with Janssen Research & Development LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement provides Janssen with a future right to evaluate a transaction related to the VC-01(TM) combination product that ViaCyte is developing for type 1 diabetes. This right will continue through the initial evaluation of clinical efficacy of VC-01. ViaCyte received $20 million from Janssen and Johnson & Johnson Development Corporation (JJDC). The payment included a rights fee and a note convertible into equity at a later date. JJDC has been a long-standing investor in ViaCyte.
Final Glance: Medical Devices companies
AP - Fri Aug 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Fri Aug 22, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:55PM CDT
Bristol-Myers (BMY) and partner Pfizer (PFE) announced that the FDA has cleared Eliquis for an additional indication.
Eli Lilly Uncovers Positive Data from Ixekizumab Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:45PM CDT
Eli Lilly and Company (LLY) announced encouraging results from three studies under theUNCOVER program on ixekizumab.
Omnicom Offers Steady Profit Growth, Rising Dividend
at Investor's Business Daily - Fri Aug 22, 4:25PM CDT
Omnicom Group (OMC), the biggest U.S. advertising company, is seeing profits improve as the global economy continues to grow. The New York City-based firm has reported two straight quarters of accelerating profit increases, to 10% in the latest...
Johnson & Johnson vs. Abbott Laboratories in the Battle for Emerging Market Turf
at The Street - Fri Aug 22, 3:55PM CDT
Emerging market pharmaceutical sales are exploding. Find out if Abbott Laboratories or Johnson & Johnson is best positioned to take advantage of the booming emerging market pharmaceutical market.
3 Reasons Bristol-Myers Squibb's Stock Could Rise
George Budwell, The Motley Fool - Motley Fool - Fri Aug 22, 3:47PM CDT
The patent cliff has forced most Big Pharmas to make major transformations in their businesses over the past few years. Bristol-Myers Squibb in particular has been ravaged by the loss of patent protection for blood thinner Plavix and a host of...
Midday Glance: Pharmaceuticals companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Johnson & Johnson (JNJ) Approaches New Downside Target of $102.89
Comtex SmarTrend(R) - Fri Aug 22, 10:24AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bearishly opened below the pivot of $103.98 today and have reached the first support level of $103.54. Should the shares continue to fall, the support pivots of $102.89 and $101.80 will be of interest.
Intel, Home Depot, Microsoft Lead DJIA During Earnings Season
at The Street - Fri Aug 22, 8:00AM CDT
On Thursday, Home Depot became the last Dow component to report quarterly results. Here's how the 30 stocks in the DJIA fared during earnings season.
Illumina lines up key partners
at Investor's Business Daily - Thu Aug 21, 5:41PM CDT
DNA sequencing gear maker Illumina (ILMN) struck strategic partnerships with several big drugmakers to develop a universal sequencing-based oncology test system for cancer diagnosis. Its initial partners for the project include AstraZeneca (AZN),...
Apple Stock Held By Institutional Investors Rises
at Investor's Business Daily - Thu Aug 21, 4:02PM CDT
Ownership of Apple (AAPL) stock by institutional investment firms edged up 1.3% in the second quarter from Q1, as confidence in the company's performance rose. The increase follows a 4.3% decline in Q1 from Q4, reports FactSet Research. Though the Q2...
Dow Component Johnson & Johnson (JNJ) To Go Ex-dividend Tomorrow
at The Street - Thu Aug 21, 10:00AM CDT
Friday, August 22, 2014 is the ex-dividend date for Dow component (NYSE:JNJ).
Must-See Charts: Still Time to Buy These 5 Stocks
at The Street - Thu Aug 21, 9:09AM CDT
Here's how to trade some of the biggest stocks on Wall Street.
Dow Today: Johnson & Johnson (JNJ) Leads The Day Higher, Boeing (BA) Lags
at The Street - Thu Aug 21, 9:00AM CDT
The Dow component leading the way higher looks to be Johnson & Johnson (NYSE:JNJ), which is sporting a 67-cent gain (+0.7%) bringing the stock to $103.88. Holding back the Dow today is Boeing (NYSE:BA), which is lagging the broader Dow index with a...
The Zacks Analyst Blog Highlights: Johnson & Johnson, Tekmira Pharmaceuticals, GileadSciences, Allergan and Supernus Pharmaceuticals
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Johnson & Johnson (NYSE:JNJ-Free Report), Tekmira Pharmaceuticals Corp (Nasdaq:TKMR-Free Report), Gilead Sciences Inc. (Nasdaq:GILD-Free Report), Allergan Inc. (NYSE:AGN-Free Report) and Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN-Free Report).
ViaCyte, Inc. Announces Signing of Rights Agreement with Janssen Research & Development LLC.
PR Newswire - Thu Aug 21, 8:00AM CDT
ViaCyte, Inc., a privately held regenerative medicine company announced today that it has entered into a Rights Agreement with Janssen Research & Development LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement provides Janssen with a future right to evaluate a transaction related to the VC-01(TM) combination product that ViaCyte is developing for type 1 diabetes. This right will continue through the initial evaluation of clinical efficacy of VC-01. ViaCyte received $20 million from Janssen and Johnson & Johnson Development Corporation (JJDC). The payment included a rights fee and a note convertible into equity at a later date. JJDC has been a long-standing investor in ViaCyte.
